This ADC product is comprised of an anti-CD33 monoclonal antibody (clone HuM195) conjugated via a AcBut linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CD33; CD33 molecule; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3;
- Target Entrez Gene ID
- 945
- Overview
- CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
ADC Antibody
- Overview
- Humanized Anti-CD33 lgG1 Antibody, clone # HuM195
ADC Linker
- Name
- AcBut [-(4' acetyl phenoxy) butanoic acid]
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
ADC payload drug
- Description
- Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products